NCT02981615View on ClinicalTrials.gov

Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2022

Conditions

Prevention

Interventions

DRUG

Levofloxacin

one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles

DRUG

Placebo Oral Tablet

one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles

Trial Locations (1)

52621

Chim Sheba Medical Center, Tel Litwinsky

All Listed Sponsors

lead

Sheba Medical Center

OTHER_GOV

NCT02981615 - Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients | Biotech Hunter | Biotech Hunter